arrow
A

Alexandre Wicky

precision oncology center
H指数:10
被引数:850

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Clinical outcomes and management following progressive disease with anti-PD-(L)1 therapy in patients with advanced Merkel Cell Carcinoma

晚期 Merkel Cell Carcinoma 患者接受抗 PD-(L)1 疗法后进展性疾病的治疗结果与管理

2025-02-010
PRE
Efficacy and safety of 'Second Adjuvant' therapy with BRAF/MEK inhibitors after local therapy for recurrent melanoma following adjuvant PD-1 based immunotherapy

基于辅助PD-1的免疫治疗后复发黑色素瘤局部治疗后使用BRAF/MEK抑制剂的 “第二佐剂” 治疗的疗效和安全性

2024-03-014
PRE
Outcomes of patients with resected stage III/IV acral or mucosal melanoma, treated with adjuvant anti-PD-1 based therapy

切除的III/IV期肢端或粘膜黑色素瘤患者的结果,以anti-PD-1为基础的辅助治疗

2024-03-016
PRE
The role of diabetes in metastatic melanoma patients treated with nivolumab plus relatlimab
2023-10-255
OAAI
Modeling tumor size dynamics based on real-world electronic health records and image data in advanced melanoma patients receiving immunotherapy
2023-06-164
OA
Multilingual RECIST classification of radiology reports using supervised learning

使用监督学习对放射学报告进行多语言RECIST分类

2023-06-141
OAAI
A differential process mining analysis of COVID-19 management for cancer patients

癌症患者新型冠状病毒肺炎管理的差异化过程挖掘分析

2022-12-074
OAAI
Systematic comparison with autoimmune liver disease identifies specific histological features of immune checkpoint inhibitor-related adverse events

与自身免疫性肝病的系统比较可确定免疫检查点抑制剂相关不良事件的特定组织学特征

2022-10-2520
OAAI
Efficacy of anti-PD-1 and ipilimumab alone or in combination in acral melanoma
2022-07-0627
OAAI
Resident Kupffer cells and neutrophils drive liver toxicity in cancer immunotherapy
2021-07-2956
OA
Original Research Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: An overlooked aspect in immunotherapy
2021-05-01103
OA